This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Cubist Focuses On Expanded Antibiotic Pipeline To Combat Infectious Diseases At IDWeek 2013

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it will focus on its expanded pipeline of antibiotics, represented through several presentations, during IDWeek 2013 being held October 2-6 in San Francisco. Presentations will feature the company’s development of antibiotics for serious infections caused by multidrug-resistant bacteria. Several presentations will also highlight the marketed antibiotic CUBICIN® (daptomycin for injection).

Presentations at IDWeek will focus on the company’s late stage candidates ceftolozane/tazobactam (formerly CXA-201) being studied for the treatment of Gram-negative bacteria and surotomycin (formerly CB-183,815) being studied for the treatment of diarrhea caused by Clostridium difficile (C. difficile), categorized as an urgent threat in the recent U.S. Centers for Disease Control and Prevention (CDC) report “Antibiotic Resistant Threats in the United States, 2013.” Presentations will also feature tedizolid phosphate, a once daily, I.V. or orally administered oxazolidinone being developed for the treatment of serious Gram-positive skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). In addition, Cubist expects to begin trials with tedizolid phosphate in gram-positive lung infections later this year. Cubist has added tedizolid to its pipeline through the recent acquisition of Trius Therapeutics. All of these candidates have been granted Fast Track status, pursuant to the GAIN Act, by the U.S. Food and Drug Administration (FDA) for their respective Qualified Infectious Disease Product (QIDP) indications.

“With the recent acquisition of Trius, Cubist is making significant traction towards meeting the IDSA challenge to industry and policy makers to develop and approve 10 new antibiotics by 2020. We are keenly focused on combatting growing antibacterial resistance and rising hospital-acquired infections,” said Steven Gilman, Ph.D., Executive Vice President of Research and Development and Chief Scientific Officer of Cubist Pharmaceuticals. “Our presentations will focus on our expanded pipeline, which includes antibiotics being developed to address pathogens contributing to the escalating global public health threat. During IDWeek we are also marking the 10 year anniversary of CUBICIN, which was developed and launched by Cubist.”

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,131.97 +100.83 0.59%
S&P 500 1,998.98 +14.85 0.75%
NASDAQ 4,552.7590 +33.8570 0.75%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs